Review



genome wide crispr cas9 screening  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc genome wide crispr cas9 screening
    Genome Wide Crispr Cas9 Screening, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/genome wide crispr cas9 screening/product/Addgene inc
    Average 93 stars, based on 9 article reviews
    genome wide crispr cas9 screening - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    genome-wide crispr activation screen  (Broad Institute Inc)
    90
    Broad Institute Inc genome-wide crispr activation screen
    Genome Wide Crispr Activation Screen, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/genome-wide crispr activation screen/product/Broad Institute Inc
    Average 90 stars, based on 1 article reviews
    genome-wide crispr activation screen - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    genome wide crispr cas9 screening  (Addgene inc)
    93
    Addgene inc genome wide crispr cas9 screening
    Genome Wide Crispr Cas9 Screening, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/genome wide crispr cas9 screening/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    genome wide crispr cas9 screening - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    genome wide crispr activation screen  (Addgene inc)
    94
    Addgene inc genome wide crispr activation screen
    Fig. 1 | <t>CRISPR</t> activation screen and transcriptome analysis of patient samples identify PRMT3 as a candidate driver for OXA resistance in HCC. a Volcano plot reveals differential gRNAs targeting genes of genome-wide <t>CRISPRa</t> screen during OXA treatment. b Volcano plot shows the differentially expressed genes identified from RNA-seq analysis of HCC patient samples treated with OXA-based HAIC (Responders VS Non-responders). c Venn diagram showing top candidate genes involved in OXA resistance based on CRISPRa screen and RNA-seq analysis of HCC patient samples. d PRMT3 sgRNAs were enriched in OXA-treated HepG2 cells compared to vehicle-treated HepG2 cells. e Comparison of PRMT3 mRNA expres- sion (FKPM) in tumors from patients treated with OXA who were defined as responders and non-responders. f The mRNA and protein level of PRMT3 in PLC-
    Genome Wide Crispr Activation Screen, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/genome wide crispr activation screen/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    genome wide crispr activation screen - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 1 | CRISPR activation screen and transcriptome analysis of patient samples identify PRMT3 as a candidate driver for OXA resistance in HCC. a Volcano plot reveals differential gRNAs targeting genes of genome-wide CRISPRa screen during OXA treatment. b Volcano plot shows the differentially expressed genes identified from RNA-seq analysis of HCC patient samples treated with OXA-based HAIC (Responders VS Non-responders). c Venn diagram showing top candidate genes involved in OXA resistance based on CRISPRa screen and RNA-seq analysis of HCC patient samples. d PRMT3 sgRNAs were enriched in OXA-treated HepG2 cells compared to vehicle-treated HepG2 cells. e Comparison of PRMT3 mRNA expres- sion (FKPM) in tumors from patients treated with OXA who were defined as responders and non-responders. f The mRNA and protein level of PRMT3 in PLC-

    Journal: Nature communications

    Article Title: PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer.

    doi: 10.1038/s41467-023-37542-5

    Figure Lengend Snippet: Fig. 1 | CRISPR activation screen and transcriptome analysis of patient samples identify PRMT3 as a candidate driver for OXA resistance in HCC. a Volcano plot reveals differential gRNAs targeting genes of genome-wide CRISPRa screen during OXA treatment. b Volcano plot shows the differentially expressed genes identified from RNA-seq analysis of HCC patient samples treated with OXA-based HAIC (Responders VS Non-responders). c Venn diagram showing top candidate genes involved in OXA resistance based on CRISPRa screen and RNA-seq analysis of HCC patient samples. d PRMT3 sgRNAs were enriched in OXA-treated HepG2 cells compared to vehicle-treated HepG2 cells. e Comparison of PRMT3 mRNA expres- sion (FKPM) in tumors from patients treated with OXA who were defined as responders and non-responders. f The mRNA and protein level of PRMT3 in PLC-

    Article Snippet: Genome-wide CRISPR activation screen In this study, the CRISPR-PoolTM SAM human library (Addgene, cat. no. 1000000074) was used to identify genes responsible for OXA resistance in HCC cells.

    Techniques: CRISPR, Activation Assay, Genome Wide, RNA Sequencing, Comparison